EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Dysregulation as a Driver of Coronary Heart Disease

Sijie Chu, Huifen Zhou, Haitong Wan

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27209149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Sijie Chu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. Hauptthemen laut MEDLINE: Coronary Disease. Die Arbeit nennt 273 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National key R & D program of China, Key R&D Program of Zhejiang, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronary heart disease (CHD) affects millions of individuals worldwide and remains a leading cause of morbidity and mortality. It compromises quality of life primarily through myocardial ischemia resulting from progressive coronary arterial narrowing and contributes to a wide range of adverse clinical outcomes. Although current therapeutic strategies, including coronary revascularization, lipid-lowering therapy, and plaque stabilization, have substantially improved patient prognosis, they do not fully address the underlying immunopathological mechanisms driving disease progression. Increasing evidence suggests that immune-mediated inflammation and vascular injury play critical roles in the initiation, progression, and destabilization of atherosclerotic plaques, highlighting the immune system as a potential therapeutic target in CHD management. In this review, we summarize recent advances in our understanding of the contributions of innate and adaptive immune responses to CHD pathogenesis. Collectively, current evidence indicates that immune dysregulation is a central driver of atherogenesis and its clinical manifestations, supporting the development of targeted immunomodulatory strategies as promising approaches for the prevention and treatment of CHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary DiseaseHumansAnimalsAdaptive ImmunityImmunity, InnateInflammationCytokinesAtherosclerosis

Stichwörter der Autor:innen

atherosclerosiscoronary heart diseaseimmune cellsinflammatory cytokines

Substanzen

Cytokines

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
  • Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.

Förderung

  • National key R & D program of China
  • Key R&D Program of Zhejiang
  • National Key R&D Program of China
  • Key R&D Program of Zhejiang Province

Zitieren

APA

Chu, S., Zhou, H., & Wan, H. (2026). Immune Dysregulation as a Driver of Coronary Heart Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209149

Vancouver

Chu S, Zhou H, Wan H. Immune Dysregulation as a Driver of Coronary Heart Disease. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209149

BibTeX
@article{Chu2026,
  author = {Chu, Sijie and Zhou, Huifen and Wan, Haitong},
  title = {Immune Dysregulation as a Driver of Coronary Heart Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27209149}
}
Kostenlos starten →